Baseline Variables Before and After Propensity Score Matching for CNST+ and CNSI Subtypes
| Before matching (n = 193) | After matching (n = 50 pairs) | ||||||
|---|---|---|---|---|---|---|---|
| Variable | CNST+ (n = 78) | CNSI (n = 115) | P* | CNST+ | CNSI | SMD | P† |
| Age | 59.15 (10.85) | 53.63 (14.25) | <0.01 | 56.66 (11.37) | 59.12 (9.43) | 0.23 | 0.50 |
| Body mass index | 23.23 (3.33) | 22.97 (1.12) | 0.43 | 22.76 (3.27) | 22.92 (1.14) | 0.05 | 0.81 |
| Male sex | 50 (64.1) | 68 (59.1) | 0.49 | 31 (62.0) | 31 (62.0) | <0.01 | 1.00 |
| Positive smoking history | 22 (28.2) | 28 (24.3) | 0.55 | 14 (28.0) | 13 (26.0) | 0.04 | 1.00 |
| Meningitis | 30 (38.5) | 38 (33.0) | 0.70 | 19 (38.0) | 19 (38.0) | <0.01 | 1.00 |
| Encephalitis | 21 (26.9) | 36 (31.3) | 17 (34.0) | 17 (34.0) | <0.01 | ||
| Meningoencephalitis | 27 (34.6) | 41 (35.7) | 14 (28.0) | 14 (28.0) | <0.01 | ||
| Concurrent target therapy | 22 (28.2) | 32 (27.8) | 0.95 | 11 (22.0) | 10 (20.0) | 0.04 | 1.00 |
| Concurrent chemotherapy | 39 (50.0) | 57 (49.6) | 0.95 | 27 (54.0) | 30 (60.0) | 0.12 | 0.68 |
| Radiotherapy history | 3 (3.8) | 6 (5.2) | 0.66 | 2 (4.0) | 3 (6.0) | 0.10 | 1.00 |
| Primary surgery | 66 (84.6) | 91 (79.1) | 0.34 | 44 (88.0) | 43 (86.0) | 0.06 | 1.00 |
| Stage of I and II | 28 (35.9) | 47 (50.9) | 0.91 | 18 (36.0) | 20 (40.0) | 0.11 | 0.80 |
| Comorbid neurologic disease | 4 (5.1) | 9 (7.8) | 0.46 | 3 (6.0) | 3 (6.0) | <0.01 | 1.00 |
| Comorbid CHF | 3 (3.8) | 7 (6.1) | 0.49 | 1 (2.0) | 1 (2.0) | <0.01 | 1.00 |
| ECOG score | 1.94 (1.15) | 2.28 (1.20) | 0.05 | 2.08 (1.10) | 2.06 (1.19) | 0.02 | 0.95 |
| Positive mental problem | 23 (29.5) | 33 (28.7) | 0.91 | 15 (30.0) | 13 (26.0) | 0.09 | 0.83 |
| Treatment | |||||||
| Atezolizumab | 9 (11.5) | 8 (7.0) | 0.37 | 6 (12.0) | 4 (8.0) | 0.12 | 0.92 |
| Camrelizumab | 5 (6.4) | 7 (6.1) | 3 (6.0) | 2 (4.0) | 0.08 | ||
| Durvalumab | 7 (9.0) | 10 (8.7) | 6 (12.0) | 5 (10.0) | 0.07 | ||
| Nivolumab | 15 (19.2) | 17 (14.8) | 12 (24.0) | 9 (18.0) | 0.15 | ||
| Pembrolizumab | 12 (15.4) | 15 (13.0) | 6 (12.0) | 8 (16.0) | −0.11 | ||
| Sintilimab | 21 (26.9) | 34 (29.6) | 11 (22.0) | 14 (28.0) | −0.13 | ||
| Tislelizumab | 0 (0.0) | 8 (7.0) | 0 (0.0) | 0 (0.0) | NA | ||
| Toripalimab | 9 (11.5) | 16 (13.9) | 6 (12.0) | 8 (16.0) | −0.12 | ||
| Cancer type | |||||||
| Nasopharyngeal carcinoma | 2 (2.6) | 15 (13.0) | 0.07 | 2 (4.0) | 4 (8.0) | 0.18 | 0.90 |
| Non–small cell lung cancer | 25 (32.1) | 23 (20.0) | 15 (30.0) | 13 (26.0) | 0.09 | ||
| Colorectal carcinoma | 14 (17.9) | 19 (16.5) | 10 (20.0) | 10 (20.0) | 0.00 | ||
| Gastric cancers | 1 (1.3) | 2 (1.7) | 0 (0.0) | 1 (2.0) | 0.18 | ||
| Esophageal cancers | 0 (0.0) | 11 (9.6) | 0 (0.0) | 0 (0.0) | NA | ||
| Hepatocellular carcinoma | 3 (3.8) | 2 (1.7) | 1 (2.0) | 2 (4.0) | 0.10 | ||
| Oral carcinoma | 2 (2.6) | 3 (2.6) | 0 (0.0) | 1 (2.0) | 0.13 | ||
| Biliary and pancreatic cancers | 0 (0.0) | 1 (0.9) | 0 (0.0) | 0 (0.0) | NA | ||
| Other cancer types | 6 (7.7) | 6 (5.2) | 3 (6.0) | 4 (8.0) | 0.07 | ||
| Lymphoma | 8 (10.3) | 6 (5.2) | 5 (10.0) | 5 (10.0) | 0.00 | ||
| Mesothelioma | 1 (1.3) | 2 (1.7) | 1 (2.0) | 1 (2.0) | 0.00 | ||
| Renal cell carcinoma | 3 (3.8) | 1 (0.9) | 2 (4.0) | 1 (2.0) | 0.10 | ||
| Urogenital cancers | 1 (1.3) | 3 (2.6) | 1 (2.0) | 2 (4.0) | 0.18 | ||
| Sarcoma | 2 (2.6) | 4 (3.5) | 2 (4.0) | 0 (0.0) | 0.25 | ||
| Unknown types | 10 (12.8) | 17 (14.8) | 8 (16.0) | 6 (12.0) | 0.12 | ||
| Whole-brain SUVmean | 4.61 (1.25) | 4.63 (1.49) | 0.92 | 4.72 (1.16) | 4.54 (1.50) | 0.15 | 0.45 |
↵* Independent t test (continuous) or χ2 test (categoric).
↵† Wilcoxon signed-rank test (continuous), McNemar nonparametric test (binary), and χ2 test (multiple categories).
SMD = standardized mean difference to show imbalance levels of variables after matching (variable with SMD > 0.25 is considered poorly matched); CHF = congestive heart failure; ECOG = Eastern Cooperative Oncology Group.
Data are number followed by percentage in parentheses, except for whole-brain SUVmean, for which SD is given in parentheses.